Vitamin E suppresses telomerase activity in ovarian cancer cells

Cancer Detection and Prevention

Volumn 31, Issue 2, 2007, Pages 119-128

  Bermudez, Yira ^a   Ahmadi, Shirrin ^a   Lowell, Nancy E ^a   Kruk, Patricia A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

hTERT; Telomerase inhibition; Vitamin E acetate

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENOL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; ALPHA TOCOPHEROL; CASPASE 3; CISPLATIN; LUCIFERASE; MESSENGER RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; EPITHELIUM CELL; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; CISPLATIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TUMOR CELLS, CULTURED; VITAMIN E;

EID: 34247623040     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.12.002     Document Type: Article

References (46)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Goodman M.T., and Howe H.L. Descriptive epidemiology of ovarian cancer in the United States 1992-1997. Cancer 97 (2003) 2615-2630
3. Ozols R.F. Ovarian cancer Part II: Treatment. Curr Probl Cancer 16 (1992) 61-126
4. Blackledge G., Lawton F., Redman C., and Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59 (1989) 650-653
5. Gordon A., Carmichael J., and Malfetano J. Final analysis of a phase III randomized study of topotecan vs. paclitaxel in advanced epithelial ovarian cancer. Intl Topotecan Study Group 17 (1997) 356a
6. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
7. Rose P.G., Blessing J.A., Mayer A.R., and Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 405-410
8. Steichen-Gersdorf E., Gallion H.H., Ford D., Girodet C., Easton D.F., DiCioccio R.A., et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 55 (1994) 870-875
9. Percy C., and Muir C. The international comparability of cancer mortality data results of an international death certificate study. Am J Epidemiol 129 (1989) 934-946
10. Negri E., Franceschi S., Tzonou A., Booth M., La Vecchia C., and Parazzini F. Pooled analysis of 3 European case-control studies. I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49 (1991) 50-56
11. Casagrande J.T., Louie E.W., Pike M.C., Roy S., Ross R.K., and Henderson B.E. Incessant ovulation" and ovarian cancer. Lancet 2 (1979) 170-173
12. Zhang X., Feng J., Cheng Y., Yao Y., Ye X., Fu T., et al. Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer 15 (2005) 50-57
13. Brekelmans C.T. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15 (2003) 63-68
14. Fairfield K.M., Hankinson S.E., Rosner B.A., Hunter D.J., Colditz G.A., and Willett W.C. Risk of ovarian carcinoma and consumption of Vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 92 (2001) 2318-2326
15. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
16. Counter C.M., Hirte H.W., Bacchetti S., and Harley C.B. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91 (1994) 2900-2904
17. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
18. Murakami J., Nagai N., and Ohama K. Telomerase activity in body cavity fluid and peritoneal washings in uterine and ovarian cancer. J Int Med Res 26 (1998) 129-139
19. 2-terminal kinase-dependent induction of telomerase by calcium requires Pyk2. Cancer Res 64 (2004) 23-26
20. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59 (1999) 551-557
21. Kiyozuka Y., Yamamoto D., Yang J., Uemura Y., Senzaki H., Adachi S., et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 20 (2000) 203-212
22. Kondo Y., Kondo S., Tanaka Y., Haqqi T., Barna B.P., and Cowell J.K. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16 (1998) 2243-2248
23. Bermudez Y., Erasso D., Johnson N., Alfonso-De Matte M., Lowell N., and Kruk P. Telomerase confers resistance to caspase-mediated apoptosis. Clin Intervent Aging 1 (2006) 155-167
24. Kruk P.A., Godwin A.K., Hamilton T.C., and Auersperg N. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 73 (1999) 229-236
25. Alfonso-De Matte M.Y., Yang H., Evans M.S., Cheng J.Q., and Kruk P.A. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 62 (2002) 4575-4578
26. Ohyashiki K., Ohyashiki J.H., and Toyama K. Technical improvement in determining telomerase activity in hematologic neoplasias: a possibility of single cell determination of telomerase activity. Hum Cell 9 (1996) 295-300
27. Yang H., Ou C.C., Feldman R.I., Nicosia S.V., Kruk P.A., and Cheng J.Q. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res 64 (2004) 463-467
28. Anderson K., Lawson K.A., Simmons-Menchaca M., Sun L., Sanders B.G., and Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood) 229 (2004) 1169-1176
29. Sabol S.L., Li R., Lee T.Y., and Abdul-Khalek R. Inhibition of apoptosis-associated DNA fragmentation activity in nonapoptotic cells: the role of DNA fragmentation factor-45 (DFF45/ICAD). Biochem Biophys Res Commun 253 (1998) 151-158
30. Sakahira H., Enari M., and Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391 (1998) 96-99
31. Schneider C. Chemistry and biology of Vitamin E. Mol Nutr Food Res 49 (2005) 7-30
32. Fleischauer A.T., Olson S.H., Mignone L., Simonsen N., Caputo T.A., and Harlap S. Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. Nutr Cancer 40 (2001) 92-98
33. Argyriou A.A., Chroni E., Koutras A., Ellul J., Papapetropoulos S., Katsoulas G., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 (2005) 26-31
34. Siewinski M., Saleh Y., Gryboc M., Murawski M., Ekonjo G.B., Ziolkowski P., et al. Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and Vitamin E. J Exp Ther Oncol 4 (2004) 189-193
35. Drisko J.A., Chapman J., and Hunter V.J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 22 (2003) 118-123
36. Nagle C.M., Purdie D.M., Webb P.M., Green A., Harvey P.W., and Bain C.J. Dietary influences on survival after ovarian cancer. Int J Cancer 106 (2003) 264-269
37. Hahn T., Szabo L., Gold M., Ramanathapuram L., Hurley L.H., and Akporiaye E.T. Dietary Administration of the Proapoptotic Vitamin E Analogue {alpha}-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res 66 (2006) 9374-9378
38. Neuzil J., Weber T., Schroder A., Lu M., Ostermann G., Gellert N., et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 15 (2001) 403-415
39. Zhang M., Altuwaijri S., and Yeh S. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 23 (2004) 3080-3088
40. Galli F., Stabile A.M., Betti M., Conte C., Pistilli A., Rende M., et al. The effect of alpha- and gamma-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch Biochem Biophys 423 (2004) 97-102
41. Fujimoto K., Kyo S., Takakura M., Kanaya T., Kitagawa Y., Itoh H., et al. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res 28 (2000) 2557-2562
42. Renaud S., Loukinov D., Bosman F.T., Lobanenkov V., and Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res 33 (2005) 6850-6860
43. Racek T., Mise N., Li Z., Stoll A., and Putzer B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J Biol Chem 280 (2005) 40402-40405
44. Chang J.T., Yang H.T., Wang T.C., and Cheng A.J. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. Mol Carcinog 44 (2005) 183-192
45. Cong Y.S., Wen J., and Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8 (1999) 137-142
46. Jha M.N., Bedford J.S., Cole W.C., Edward-Prasad J., and Prasad K.N. Vitamin E (d-alpha-tocopheryl succinate) decreases mitotic accumulation in gamma-irradiated human tumor, but not in normal, cells. Nutr Cancer 35 (1999) 189-194